No quarterly revenue total was found in Nkarta, Inc.'s SEC filings.
Nkarta, Inc. (NKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$27.1 million. As of Sep 30, 2026 it held $213.3 million in cash and investments and $72.0 million in total debt.
Revenue
—
Net income
$-33.33M
-53.5% vs year-ago quarter
Operating cash flow
$-25.84M
-38.3% vs year-ago quarter
Free cash flow
$-27.08M
-44.9% vs year-ago quarter
EPS
$-0.45
-55.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
71.70M
+1.0% vs year-ago quarter
Net cash
$141.25M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1787400
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$35.8M | -$43.1M | -$30.9M | -$31.0M | -$27.3M |
| Net income | -$33.3M | -$40.4M | -$27.8M | -$27.4M | -$21.7M |
| Diluted EPS | -$0.45 | -$0.54 | -$0.37 | -$0.37 | -$0.29 |
| Operating cash flow | -$25.8M | -$24.2M | -$28.2M | -$21.6M | -$18.7M |
| Free cash flow | -$27.1M | -$24.4M | -$28.6M | -$22.2M | -$18.7M |
| Total assets | $308.5M | $337.6M | $372.1M | $404.2M | $427.2M |
| Total liabilities | $92.7M | $89.9M | $86.2M | $91.9M | $89.3M |
| Stockholders' equity | $215.7M | $247.7M | $285.9M | $312.3M | $337.9M |
| Cash and investments | $213.3M | $240.4M | $264.0M | $292.4M | $313.8M |
| Total debt | $72.0M | $73.5M | $75.0M | $76.4M | $76.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 6, 2026 | Nov 6, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 439 Nkarta, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.